Document is current

Any future updates will be listed below

Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

Crossref DOI link: https://doi.org/10.1007/s12032-014-0474-x

Published Online: 2015-01-25

Published Print: 2015-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark